Copeptin and mid-regional pro-atrial natriuretic peptide in women with suspected or confirmed pre-eclampsia: comparison with sFlt-1/PlGF ratio

Ultrasound Obstet Gynecol. 2020 Dec;56(6):872-878. doi: 10.1002/uog.21979.

Abstract

Objectives: Arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) may contribute to the pathogenesis of pre-eclampsia (PE), but their role remains to be elucidated. Our aims were to evaluate the surrogates of AVP and ANP, C-terminal pro-AVP (copeptin) and mid-regional pro-ANP (MR-proANP), as biomarkers for the prediction of PE-related pregnancy complications and whether they are associated with angiogenic markers and/or clinical manifestations of PE.

Methods: This was a retrospective analysis of a prospective cohort study that enrolled pregnant women with suspected or confirmed PE, between December 2013 and April 2016. From each patient, a blood sample was obtained at study entry and serum levels of copeptin, MR-proANP, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) were measured. We evaluated the ability of sFlt-1, PlGF, sFlt-1/PlGF ratio, copeptin and MR-proANP, assessed either alone or combined with traditional predictors (gestational age, parity, diastolic blood pressure and proteinuria), to predict maternal complications and fetal/neonatal complications. Models were compared using concordance statistic (C-index).

Results: A total of 526 women were evaluated in the study. Women with confirmed PE displayed elevated serum copeptin and MR-proANP levels in comparison to those with suspected PE but no hypertensive disease of pregnancy. When combined with traditional predictors, the sFlt-1/PlGF ratio displayed a higher C-index than copeptin and MR-proANP (0.76, 0.63 and 0.67, respectively, vs 0.60 for the traditional predictors alone) for the prediction of maternal complications. Similarly, for the prediction of fetal/neonatal complications, the sFlt-1/PlGF ratio displayed a higher C-index than copeptin and MR-proANP when added to the traditional model (0.83, 0.79 and 0.80, respectively, vs 0.79 for the traditional predictors alone). When subdividing women according to sFlt-1/PlGF ratio (≥ 85 vs < 85), no differences in copeptin levels were observed, while MR-proANP level was elevated in women with sFlt-1/PlGF ratio ≥ 85. Multiple regression analysis revealed that copeptin and MR-proANP were independent determinants of proteinuria.

Conclusions: Copeptin and MR-proANP have limited value in predicting PE-related complications when compared with the sFlt-1/PlGF ratio. However, both copeptin and MR-proANP were associated with proteinuria, with copeptin exerting this effect independently of the sFlt-1/PlGF ratio. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.

Keywords: PlGF; angiogenesis; atrial natriuretic peptide; biomarkers; copeptin; pre-eclampsia; prediction; sFlt-1.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Atrial Natriuretic Factor / blood*
  • Biomarkers / blood
  • Female
  • Gestational Age
  • Glycopeptides / blood*
  • Humans
  • Maternal Serum Screening Tests / methods
  • Maternal Serum Screening Tests / statistics & numerical data*
  • Placenta Growth Factor / blood
  • Pre-Eclampsia / blood*
  • Pre-Eclampsia / diagnosis*
  • Predictive Value of Tests
  • Pregnancy
  • Prospective Studies
  • Retrospective Studies
  • Vascular Endothelial Growth Factor Receptor-1 / blood

Substances

  • Biomarkers
  • Glycopeptides
  • PGF protein, human
  • copeptins
  • midregional pro-atrial natriuretic peptide, human
  • Placenta Growth Factor
  • Atrial Natriuretic Factor
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1